Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the valsartan heart failure trial (Val-HeFT)

Lawrence Baruch, Robert D. Glazer, Nora Aknay, Johan Vanhaecke, J. Thomas Heywood, Inder Anand, Henry Krum, Allen Hester, Jay N Cohn

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background The Valsartan Heart Failure Trial (Val-HeFT) demonstrated the favorable effects of the addition of valsartan to prescribed heart failure (HF) therapy on HF hospitalization, and functional and physiological parameters. As the prevalence of HF morbidity and mortality are increased in the elderly, the effect of valsartan in the elderly is of clinical significance. Methods In this post-hoc analysis, morbidity, mortality, left ventricular (LV) size and function, brain natriuretic peptide (BNP), aldosterone, norepinephrine (NE), quality of life, and treatment effect with valsartan were examined by subgroups of 2350 elderly (≥ 65 years) and 2660 non-elderly (< 65 years) patients enrolled in Val-HeFT. Results While the overall incidence of morbidity and mortality was higher in the elderly, valsartan produced beneficial effects in reducing risk of morbidity in the elderly by 11.8% (P = .07), and the non-elderly by 14.6% (P = .09). Valsartan had no effect on mortality compared to placebo in the non-elderly, 15.2% vs 15.0% (P = .87), and elderly, 25.1% vs 24.0%, (P = .64). Valsartan had statistically significant beneficial effects in both the elderly and non-elderly on LV size and function, BNP, aldosterone and quality of life. Beneficial effects on NE were also observed with valsartan in both subgroups with statistically significant reductions produced in the non-elderly. Conclusions Val-HeFT demonstrated that elderly patients present with more advanced HF as evidenced by higher morbidity and mortality along with greater neurohormonal activation. In Val-HeFT, valsartan produced a consistent beneficial effect on morbidity, LV function and size, quality of life, and neurohormonal levels in both the elderly and non-elderly.

Original languageEnglish (US)
Pages (from-to)951-957
Number of pages7
JournalAmerican Heart Journal
Volume148
Issue number6
DOIs
StatePublished - Dec 1 2004

Fingerprint

Valsartan
Heart Failure
Morbidity
Mortality
Left Ventricular Function
Brain Natriuretic Peptide
Quality of Life
Aldosterone
Norepinephrine

Cite this

Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the valsartan heart failure trial (Val-HeFT). / Baruch, Lawrence; Glazer, Robert D.; Aknay, Nora; Vanhaecke, Johan; Thomas Heywood, J.; Anand, Inder; Krum, Henry; Hester, Allen; Cohn, Jay N.

In: American Heart Journal, Vol. 148, No. 6, 01.12.2004, p. 951-957.

Research output: Contribution to journalArticle

Baruch, Lawrence ; Glazer, Robert D. ; Aknay, Nora ; Vanhaecke, Johan ; Thomas Heywood, J. ; Anand, Inder ; Krum, Henry ; Hester, Allen ; Cohn, Jay N. / Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the valsartan heart failure trial (Val-HeFT). In: American Heart Journal. 2004 ; Vol. 148, No. 6. pp. 951-957.
@article{e30b46a9316e47bea4b3063cc89ccbea,
title = "Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the valsartan heart failure trial (Val-HeFT)",
abstract = "Background The Valsartan Heart Failure Trial (Val-HeFT) demonstrated the favorable effects of the addition of valsartan to prescribed heart failure (HF) therapy on HF hospitalization, and functional and physiological parameters. As the prevalence of HF morbidity and mortality are increased in the elderly, the effect of valsartan in the elderly is of clinical significance. Methods In this post-hoc analysis, morbidity, mortality, left ventricular (LV) size and function, brain natriuretic peptide (BNP), aldosterone, norepinephrine (NE), quality of life, and treatment effect with valsartan were examined by subgroups of 2350 elderly (≥ 65 years) and 2660 non-elderly (< 65 years) patients enrolled in Val-HeFT. Results While the overall incidence of morbidity and mortality was higher in the elderly, valsartan produced beneficial effects in reducing risk of morbidity in the elderly by 11.8{\%} (P = .07), and the non-elderly by 14.6{\%} (P = .09). Valsartan had no effect on mortality compared to placebo in the non-elderly, 15.2{\%} vs 15.0{\%} (P = .87), and elderly, 25.1{\%} vs 24.0{\%}, (P = .64). Valsartan had statistically significant beneficial effects in both the elderly and non-elderly on LV size and function, BNP, aldosterone and quality of life. Beneficial effects on NE were also observed with valsartan in both subgroups with statistically significant reductions produced in the non-elderly. Conclusions Val-HeFT demonstrated that elderly patients present with more advanced HF as evidenced by higher morbidity and mortality along with greater neurohormonal activation. In Val-HeFT, valsartan produced a consistent beneficial effect on morbidity, LV function and size, quality of life, and neurohormonal levels in both the elderly and non-elderly.",
author = "Lawrence Baruch and Glazer, {Robert D.} and Nora Aknay and Johan Vanhaecke and {Thomas Heywood}, J. and Inder Anand and Henry Krum and Allen Hester and Cohn, {Jay N}",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.ahj.2004.06.001",
language = "English (US)",
volume = "148",
pages = "951--957",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the valsartan heart failure trial (Val-HeFT)

AU - Baruch, Lawrence

AU - Glazer, Robert D.

AU - Aknay, Nora

AU - Vanhaecke, Johan

AU - Thomas Heywood, J.

AU - Anand, Inder

AU - Krum, Henry

AU - Hester, Allen

AU - Cohn, Jay N

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Background The Valsartan Heart Failure Trial (Val-HeFT) demonstrated the favorable effects of the addition of valsartan to prescribed heart failure (HF) therapy on HF hospitalization, and functional and physiological parameters. As the prevalence of HF morbidity and mortality are increased in the elderly, the effect of valsartan in the elderly is of clinical significance. Methods In this post-hoc analysis, morbidity, mortality, left ventricular (LV) size and function, brain natriuretic peptide (BNP), aldosterone, norepinephrine (NE), quality of life, and treatment effect with valsartan were examined by subgroups of 2350 elderly (≥ 65 years) and 2660 non-elderly (< 65 years) patients enrolled in Val-HeFT. Results While the overall incidence of morbidity and mortality was higher in the elderly, valsartan produced beneficial effects in reducing risk of morbidity in the elderly by 11.8% (P = .07), and the non-elderly by 14.6% (P = .09). Valsartan had no effect on mortality compared to placebo in the non-elderly, 15.2% vs 15.0% (P = .87), and elderly, 25.1% vs 24.0%, (P = .64). Valsartan had statistically significant beneficial effects in both the elderly and non-elderly on LV size and function, BNP, aldosterone and quality of life. Beneficial effects on NE were also observed with valsartan in both subgroups with statistically significant reductions produced in the non-elderly. Conclusions Val-HeFT demonstrated that elderly patients present with more advanced HF as evidenced by higher morbidity and mortality along with greater neurohormonal activation. In Val-HeFT, valsartan produced a consistent beneficial effect on morbidity, LV function and size, quality of life, and neurohormonal levels in both the elderly and non-elderly.

AB - Background The Valsartan Heart Failure Trial (Val-HeFT) demonstrated the favorable effects of the addition of valsartan to prescribed heart failure (HF) therapy on HF hospitalization, and functional and physiological parameters. As the prevalence of HF morbidity and mortality are increased in the elderly, the effect of valsartan in the elderly is of clinical significance. Methods In this post-hoc analysis, morbidity, mortality, left ventricular (LV) size and function, brain natriuretic peptide (BNP), aldosterone, norepinephrine (NE), quality of life, and treatment effect with valsartan were examined by subgroups of 2350 elderly (≥ 65 years) and 2660 non-elderly (< 65 years) patients enrolled in Val-HeFT. Results While the overall incidence of morbidity and mortality was higher in the elderly, valsartan produced beneficial effects in reducing risk of morbidity in the elderly by 11.8% (P = .07), and the non-elderly by 14.6% (P = .09). Valsartan had no effect on mortality compared to placebo in the non-elderly, 15.2% vs 15.0% (P = .87), and elderly, 25.1% vs 24.0%, (P = .64). Valsartan had statistically significant beneficial effects in both the elderly and non-elderly on LV size and function, BNP, aldosterone and quality of life. Beneficial effects on NE were also observed with valsartan in both subgroups with statistically significant reductions produced in the non-elderly. Conclusions Val-HeFT demonstrated that elderly patients present with more advanced HF as evidenced by higher morbidity and mortality along with greater neurohormonal activation. In Val-HeFT, valsartan produced a consistent beneficial effect on morbidity, LV function and size, quality of life, and neurohormonal levels in both the elderly and non-elderly.

UR - http://www.scopus.com/inward/record.url?scp=10644255525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644255525&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2004.06.001

DO - 10.1016/j.ahj.2004.06.001

M3 - Article

C2 - 15632877

AN - SCOPUS:10644255525

VL - 148

SP - 951

EP - 957

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -